RxDoctor Payments Data

Patrick Keefe, DO

Family Medicine · Henderson, NVNPI 1124519970

Payments from drug & device makers

$2,287in general payments, 2019–2025

Across 31 payments — averaging $73.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$794
  • AstraZeneca$440
  • Bayer$234
  • Lilly USA, LLC$140
  • Novo Nordisk$134
  • Abbott$129
  • plus $415 from 8 others

What the payments were for

  • Food & beverage$2,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,287 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$48,631
Medicare patients
216
Services billed
693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$34,701
JardianceEmpagliflozin15$23,158
FarxigaDapagliflozin Propanediol20$19,877
OzempicSemaglutide11$16,162
SynthroidLevothyroxine Sodium13$1,191
Atorvastatin Calcium98$1,040
Ezetimibe12$880
Rosuvastatin Calcium43$802
Gabapentin36$793
Levothyroxine Sodium40$601
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide35$568
Ibuprofen52$522
Metformin Hcl46$518
Omeprazole33$489
Fluticasone Propionate30$463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$68$34,70143 claims
Boehringer IngelheimJardiance$794$23,15815 claims
AstraZenecaFarxiga$440$19,87720 claims
Novo NordiskOzempic$134$16,16211 claims
AbbVieSynthroid$16$1,19113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 902 family medicine providers in Nevada.

Other family medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →